A tool is needed to distinguish type 1 diabetes (T1D) and type 2 diabetes (T2D) in adults with new-onset diabetes because correct classification is needed for correct diagnoses and treatments. Current classification methods are usually applied to biomarkers using binary or quantitative classification with a cut point and may not be adequately nuanced. Combinations of clinical features are not necessarily specific for classifying and may not always indicate a single diagnosis. A probabilistic decision tree classification tool with multiple branches per decision node is needed for adults with new-onset diabetes to avoid misdiagnosis of actual T1D as T2D, misdiagnosis of actual T2D or monogenic diabetes as T1D, and misclassified patients in future population health studies which will lead to incorrect conclusions and suboptimal patient outcomes.
LeslieRDEvans-MolinaCFreund-BrownJ, et al. Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care. 2021;44(11):2449-2456. doi:10.2337/dc21-0770.
3.
MohanVDeepaRDeepaMSomannavarSDattaM.A simplified Indian diabetes risk score for screening for undiagnosed diabetic subjects. J Assoc Physicians India. 2005;53:759-763.
4.
MuñozCFloreenAGareyC, et al. Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives. Clin Diabetes. 2019;37(3):276-281. doi:10.2337/cd18-0088.
5.
ThomasNJLynamALHillAV, et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019;62(7):1167-1172. doi:10.1007/s00125-019-4863-8.
6.
HoltRIGDeVriesJHHess-FischlA, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589-2625. doi:10.2337/dci21-0043.
7.
HörberSAchenbachPSchleicherEPeterA.Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnol Adv. 2020;39:107359. doi:10.1016/j.biotechadv.2019.02.015.
8.
ImagawaAHanafusaTMiyagawaJMatsuzawaY.A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342(5):301-307. doi:10.1056/NEJM200002033420501.
9.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):S81-S90. doi:10.2337/dc14-S081.
10.
BravisVKaurAWalkeyHC, et al. Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open. 2018;8(4):e020904. doi:10.1136/bmjopen-2017-020904.
11.
TosurMHuangXInglisASAguirreRSRedondoMJ.Inaccurate diagnosis of diabetes type in youth: prevalence, characteristics, and implications. Sci Rep. 2024;14(1):8876. doi:10.1038/s41598-024-58927-6.
ManovAEChauhanSDhillonGDonepudiA.Unmasking type 1 diabetes in adults: insights from two cases revealing misdiagnosis as type 2 diabetes, with emphasis on autoimmunity and continuous glucose monitoring. Cureus. 2023;15(7):e42459. doi:10.7759/cureus.42459.
14.
ThomasNJJonesAG.The challenges of identifying and studying type 1 diabetes in adults. Diabetologia. 2023;66(12):2200-2212. doi:10.1007/s00125-023-06004-4.
15.
BuzzettiRTuomiTMauricioD, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes. 2020;69(10):2037-2047. doi:10.2337/dbi20-0017.
16.
KrauseMDe VitoG.Type 1 and type 2 diabetes mellitus: commonalities, differences and the importance of exercise and nutrition. Nutrients. 2023;15(19):4279. doi:10.3390/nu15194279.
17.
UmpierrezGEDavisGMElSayedNA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257-1275. doi:10.2337/dci24-0032.
18.
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care. 2025;48(suppl 1):S27-S49. doi:10.2337/dc25-S002.
19.
BielkaWPrzezakAMolędaPPius-SadowskaEMachalińskiB.Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition. Cardiovasc Diabetol. 2024;23(1):62. doi:10.1186/s12933-024-02145-x.
20.
RedondoMJMorganNG.Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19(9):542-554. doi:10.1038/s41574-023-00853-0.
StoneSIBalasubramanyamAPoseyJE.Atypical diabetes: what have we learned and what does the future hold?Diabetes Care. 2024;47(5):770-781. doi:10.2337/dci23-0038.
23.
MakahlehLOthmanAVedantamVVedantamN.Ketosis-prone type 2 diabetes mellitus: an unusual presentation. Cureus. 2022;14(10):e30031. doi:10.7759/cureus.30031.
24.
Kubota-MishraEHuangXMinardCG, et al. High prevalence of A-β+ ketosis-prone diabetes in children with type 2 diabetes and diabetic ketoacidosis at diagnosis: evidence from the rare and atypical diabetes network (RADIANT). Pediatr Diabetes. 2024;2024:5907924. doi:10.1155/2024/5907924.
25.
PatelSKMaCSFourlanosSGreenfieldJR. Autoantibody-negative type 1 diabetes: a neglected subtype. Trends Endocrinol Metab. 2021;32(5):295-305. doi:10.1016/j.tem.2021.02.001.
26.
BurrackALMartinovTFifeBT.T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes. Front Endocrinol (Lausanne). 2017;8:343. doi:10.3389/fendo.2017.00343.
27.
PihokerCGilliamLKHampeCSLernmarkA.Autoantibodies in diabetes. Diabetes. 2005;54(suppl 2):S52-S61. doi:10.2337/diabetes.54.suppl_2.s52.
28.
MilotaTŠumníkZObermannováB, et al. Negativity for specific autoantibodies in patients with type 1 diabetes that developed on a background of common variable immunodeficiency. Int Arch Allergy Immunol. 2015;168(3):197-204. doi:10.1159/000441723.
29.
JiaXYuL.Effective assay technologies fit for large-scale population screening of type 1 diabetes. Front Clin Diabetes Healthc. 2022;3:1034698. doi:10.3389/fcdhc.2022.1034698.
30.
NiskanenLKTuomiTKarjalainenJGroopLCUusitupaMI.GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995;18(12):1557-1565. doi:10.2337/diacare.18.12.1557.
31.
PatelSKFourlanosSGreenfieldJR. Classification of type 1 diabetes: a pathogenic and treatment-based classification. Diabetes Metab Syndr. 2024;18(3):102986. doi:10.1016/j.dsx.2024.102986.
32.
Abdel-KarimTHarisBAfyouniH, et al. The epidemiology and genetic analysis of children with idiopathic type 1 diabetes in the state of Qatar. J Endocr Soc. 2021;5(10):bvab131. doi:10.1210/jendso/bvab131.
33.
ZieglerAGBonifacioE; BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55(7):1937-1943. doi:10.1007/s00125-012-2472-x.
34.
ZhangHColcloughKGloynALPollinTI.Monogenic diabetes: a gateway to precision medicine in diabetes. J Clin Invest. 2021;131(3):e142244. doi:10.1172/JCI142244.
35.
HarrisAGLetourneauLRGreeleySAW. Monogenic diabetes: the impact of making the right diagnosis. Curr Opin Pediatr. 2018;30(4):558-567. doi:10.1097/MOP.0000000000000643.
36.
HoffmanLSFoxTJAnastasopoulouCJialalI.Maturity Onset Diabetes in the Young. Treasure Island, FL: StatPearls Publishing; 2023. Accessed October 8, 2024. https://www.ncbi.nlm.nih.gov/books/NBK532900/
37.
YeungROAl JundiMGubbiS, et al. Management of mitochondrial diabetes in the era of novel therapies. J Diabetes Complications. 2021;35(1):107584. doi:10.1016/j.jdiacomp.2020.107584.
38.
BalasubramanyamA.Defining and classifying new subgroups of diabetes. Annu Rev Med. 2021;72:63-74. doi:10.1146/annurev-med-050219-034524.
39.
LebovitzHEBanerjiMA.Ketosis-prone diabetes (Flatbush diabetes): an emerging worldwide clinically important entity. Curr Diab Rep. 2018;18(11):120. doi:10.1007/s11892-018-1075-4.
40.
XieXWuCHaoY, et al. Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review. Front Endocrinol (Lausanne). 2023;14:1301093. doi:10.3389/fendo.2023.1301093.
41.
ShankarMChowdhuryTGousyNParthasarathiA.An insight into Flatbush diabetes: a rare form of diabetes. Cureus. 2022;14(1):e21567. doi:10.7759/cureus.21567.
42.
LynamAMcDonaldTHillA, et al. Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years. BMJ Open. 2019;9(9):e031586. doi:10.1136/bmjopen-2019-031586.
43.
FoteinopoulouEClarkeCALPattendenRJ, et al. Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of type 1 diabetes. Diabet Med. 2021;38(7):e14449. doi:10.1111/dme.14449.
44.
Iparraguirre-VillanuevaOEspinola-LinaresKFlores CastañedaROCabanillas-CarbonellM.Application of machine learning models for early detection and accurate classification of type 2 diabetes. Diagn Basel Switz. 2023;13(14):2383. doi:10.3390/diagnostics13142383.
45.
LugnerMRawshaniAHellerydEEliassonB.Identifying top ten predictors of type 2 diabetes through machine learning analysis of UK Biobank data. Sci Rep. 2024;14(1):2102. doi:10.1038/s41598-024-52023-5.
46.
MetwallyAAPerelmanDParkH, et al. Prediction of metabolic subphenotypes of type 2 diabetes via continuous glucose monitoring and machine learning. Nat Biomed Eng. 2024. doi:10.1038/s41551-024-01311-6.
47.
TanHShiYYueT, et al. Machine learning approach reveals microbiome, metabolome, and lipidome profiles in type 1 diabetes. J Adv Res. 2024;64:213-221. doi:10.1016/j.jare.2023.11.025.
